JP2024542095A5 - - Google Patents
Info
- Publication number
- JP2024542095A5 JP2024542095A5 JP2024526574A JP2024526574A JP2024542095A5 JP 2024542095 A5 JP2024542095 A5 JP 2024542095A5 JP 2024526574 A JP2024526574 A JP 2024526574A JP 2024526574 A JP2024526574 A JP 2024526574A JP 2024542095 A5 JP2024542095 A5 JP 2024542095A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cycle
- administered
- dose
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306552 | 2021-11-05 | ||
| EP21306552.7 | 2021-11-05 | ||
| US202263381707P | 2022-10-31 | 2022-10-31 | |
| US63/381,707 | 2022-10-31 | ||
| PCT/EP2022/080776 WO2023079057A1 (en) | 2021-11-05 | 2022-11-04 | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542095A JP2024542095A (ja) | 2024-11-13 |
| JP2024542095A5 true JP2024542095A5 (https=) | 2025-11-11 |
Family
ID=84365654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526574A Pending JP2024542095A (ja) | 2021-11-05 | 2022-11-04 | 抗ｃｅａｃａｍ５抗体－薬物コンジュゲート及び抗ｖｅｇｆｒ－２抗体を含む抗腫瘍組合せ |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4426736A1 (https=) |
| JP (1) | JP2024542095A (https=) |
| KR (1) | KR20240099412A (https=) |
| AU (1) | AU2022382383A1 (https=) |
| CA (1) | CA3237142A1 (https=) |
| IL (1) | IL312519A (https=) |
| MX (1) | MX2024005484A (https=) |
| TW (1) | TW202333797A (https=) |
| WO (1) | WO2023079057A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| WO2024250925A1 (en) * | 2023-06-05 | 2024-12-12 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-ceacam5 antibodies |
| WO2025169012A1 (en) * | 2024-02-06 | 2025-08-14 | Sanofi | Methods of treating ceacam5-expressing cancers |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| JP2001522241A (ja) | 1997-04-10 | 2001-11-13 | ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ | 診断方法および試薬 |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| WO2004094613A2 (en) | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| MX338397B (es) | 2007-08-29 | 2016-04-15 | Sanofi Aventis | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| EP4138924A1 (en) * | 2020-04-24 | 2023-03-01 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri |
-
2022
- 2022-11-04 AU AU2022382383A patent/AU2022382383A1/en active Pending
- 2022-11-04 JP JP2024526574A patent/JP2024542095A/ja active Pending
- 2022-11-04 CA CA3237142A patent/CA3237142A1/en active Pending
- 2022-11-04 IL IL312519A patent/IL312519A/en unknown
- 2022-11-04 WO PCT/EP2022/080776 patent/WO2023079057A1/en not_active Ceased
- 2022-11-04 TW TW111142156A patent/TW202333797A/zh unknown
- 2022-11-04 EP EP22813952.3A patent/EP4426736A1/en active Pending
- 2022-11-04 KR KR1020247018530A patent/KR20240099412A/ko active Pending
- 2022-11-04 MX MX2024005484A patent/MX2024005484A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024542095A5 (https=) | ||
| Fu et al. | DNA damaging agent-based antibody-drug conjugates for cancer therapy | |
| JP7386208B2 (ja) | 抗ｆｏｌｒ１免疫抱合体投薬レジメン | |
| JP2025016545A5 (https=) | ||
| RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
| JP2018127469A5 (https=) | ||
| JP2021102648A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| JP2023022328A5 (https=) | ||
| SI2582728T1 (en) | Human Antibodies Conjugates against a Tissue Factor | |
| CA3093731A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2022519273A5 (https=) | ||
| JP2024545428A5 (https=) | ||
| TWI897953B (zh) | 包含抗ｃｅａｃａｍ５抗體接合物、三氟胸苷和替吡嘧啶的抗腫瘤組合 | |
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2024545427A5 (https=) | ||
| TW202417055A (zh) | 抗ｓｅｚ６抗體藥物接合物 | |
| JP2023522392A (ja) | 抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ | |
| JP2022513386A5 (https=) | ||
| WO2023079057A1 (en) | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies | |
| WO2021214223A1 (en) | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox | |
| JP2020534326A (ja) | イムノコンジュゲートにおけるメチオニン酸化を防止する方法 | |
| JPWO2021251459A5 (https=) | ||
| JP2024528917A5 (https=) | ||
| JP2025508380A5 (https=) | ||
| RU2024115286A (ru) | Противоопухолевые комбинации, содержащие конъюгаты антитела к ceacam5 и лекарственного средства и антитела к vegfr-2 |